Summary
This phase 3 randomised controlled trial evaluated perioperative durvalumab combined with neoadjuvant gemcitabine-cisplatin chemotherapy in 1,063 cisplatin-eligible patients with muscle-invasive bladder cancer. The addition of durvalumab significantly improved event-free survival (67.8% vs 59.8% at 24 months) and overall survival (82.2% vs 75.2% at 24 months) compared to chemotherapy alone, with comparable safety profiles between groups.
UK applicability
These findings may be relevant to UK oncology practice, where muscle-invasive bladder cancer treatment follows similar standards. However, applicability to UK NHS settings would depend on cost-effectiveness assessment, drug availability, and integration with current treatment pathways.
Key measures
Event-free survival at 24 months (primary endpoint); overall survival at 24 months (key secondary endpoint); grade 3–4 treatment-related adverse events; treatment-related deaths; radical cystectomy completion rates
Outcomes reported
The study measured event-free survival and overall survival at 24 months in patients with muscle-invasive bladder cancer treated with perioperative durvalumab plus neoadjuvant chemotherapy versus chemotherapy alone. Secondary outcomes included treatment-related adverse events and rates of radical cystectomy completion.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.